Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2005-10-18
2005-10-18
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S451000, C424S452000, C424S457000, C424S458000, C424S464000, C424S465000, C424S469000
Reexamination Certificate
active
06955821
ABSTRACT:
The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin and at least one additional drug ingredient. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin, wherein one or both portions has at least one additional drug ingredient. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
REFERENCES:
patent: 3065143 (1962-11-01), Christenson et al.
patent: 3362880 (1968-01-01), Sampson
patent: 3362881 (1968-01-01), Klaus et al.
patent: 3555151 (1971-01-01), Kaplan et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3981984 (1976-09-01), Signorino
patent: 4122157 (1978-10-01), Huber
patent: 4140755 (1979-02-01), Sheth et al.
patent: 4167558 (1979-09-01), Sheth et al.
patent: 4226849 (1980-10-01), Schor
patent: 4248857 (1981-02-01), DeNeale et al.
patent: 4248858 (1981-02-01), Guley et al.
patent: 4259314 (1981-03-01), Lowey
patent: 4309404 (1982-01-01), DeNeale et al.
patent: 4309405 (1982-01-01), Guley et al.
patent: 4357469 (1982-11-01), Schor
patent: 4369172 (1983-01-01), Schor et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4424235 (1984-01-01), Sheth et al.
patent: 4540566 (1985-09-01), Davis et al.
patent: 4543370 (1985-09-01), Porter et al.
patent: 4680323 (1987-07-01), Lowey
patent: 4695464 (1987-09-01), Alderman
patent: 4699779 (1987-10-01), Palinczar
patent: 4704285 (1987-11-01), Alderman
patent: 4756911 (1988-07-01), Drost et al.
patent: 4795643 (1989-01-01), Seth
patent: 4798725 (1989-01-01), Patel
patent: 4851392 (1989-07-01), Shaw et al.
patent: 4871548 (1989-10-01), Edgren et al.
patent: 4968508 (1990-11-01), Oren et al.
patent: 4980170 (1990-12-01), Schneider et al.
patent: 4983398 (1991-01-01), Gaylord et al.
patent: 4994276 (1991-02-01), Baichwal et al.
patent: 5032406 (1991-07-01), Dansereau et al.
patent: 5047248 (1991-09-01), Calanchi et al.
patent: 5098715 (1992-03-01), McCabe et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5164398 (1992-11-01), Sims et al.
patent: 5200193 (1993-04-01), Radebaugh et al.
patent: 5286493 (1994-02-01), Oshlack et al.
patent: 5292534 (1994-03-01), Valentine et al.
patent: 5326571 (1994-07-01), Wright et al.
patent: 5395626 (1995-03-01), Kotwal et al.
patent: 5403593 (1995-04-01), Royce
patent: 5427799 (1995-06-01), Valentine et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5451409 (1995-09-01), Rencher et al.
patent: 5472704 (1995-12-01), Santus et al.
patent: 5494681 (1996-02-01), Cuca et al.
patent: 5593694 (1997-01-01), Hayashida et al.
patent: 5650169 (1997-07-01), Conte et al.
patent: 5656296 (1997-08-01), Khan et al.
patent: 5662933 (1997-09-01), Baichwal et al.
patent: 5780057 (1998-07-01), Conte et al.
patent: 5807580 (1998-09-01), Luber
patent: 5840329 (1998-11-01), Bai
patent: 5945123 (1999-08-01), Hermelin
patent: 5968554 (1999-10-01), Beiman et al.
patent: 6210710 (2001-04-01), Skinner
patent: 6217903 (2001-04-01), Skinner
patent: 6372252 (2002-04-01), Blume et al.
patent: 0409781 (1994-06-01), None
patent: 2255344 (1992-11-01), None
patent: WO 87/00044 (1987-01-01), None
patent: WO 98/22097 (1998-05-01), None
Coated Pharmaceutical Dosage Forms, Bauer et al, MedPharm Scientific Publishers (1998), p. 83.
Welling, P.G., “Oral Controlled Drug Administration: Pharmacokinetic Considerations, ” Drug Dev. Ind. Pharm., 9, 1185-1225 (1983).
Kim, C., “Pharmacokinetic Considerations in the Design of Controlled Release Dosage Forms,” Controlled Release Dosage Form Design, ch. 11 (Technomic Publishing Co., Inc. 2000).
Bodmeier, R. et al., “Prolonged Release Multiple-Unit Dosage Forms Based On Water-Soluble Cellulosic Polymers or Aqueous Latexes,”Proceed. Intern. Sump. Control. Rel. Bioact. Mater., 18 (1991), Controlled Release Society, Inc.
Blume Ralph W.
Davis Robert D.
Keyser Donald Jeffrey
Adams Laboratories, Inc.
Hunton & Williams LLP
Page Thurman K.
Tran S.
LandOfFree
Sustained release formulations of guaifenesin and additional... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release formulations of guaifenesin and additional..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulations of guaifenesin and additional... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3457761